News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study


Posted on: 02/15/2008

Case Studies/Case Illustration

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study

Amy B. Heimberger, Wei Sun, S. Farzana Hussain, Mahua Dey, Lamonne Crutcher, Ken Aldape, Mark Gilbert, Samuel J. Hassenbusch, Raymond Sawaya, Bob Schmittling, Gary E. Archer, Duane A. Mitchell, Darell D. Bigner and John H. Sampson

Departments of Neurosurgery (A.B.H., W.S., S.F.H., L.C., S.J.H., R.S.), Neuropathology (K.A.), and Neuro-Oncology (M.G.), The University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Neurosurgery, Baylor College of Medicine, Houston, TX (A.B.H., M.D., S.J.H., R.S.); and Division of Neurosurgery, Departments of Surgery (B.S., G.E.A., D.A.M., J.H.S.) and Pathology (D.D.B., J.H.S.), Duke University Medical Center, Durham, NC; USA

Address correspondence to Amy B. Heimberger, Unit 442, Department of Neurosurgery, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA (aheimber@mdanderson.org ).

Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization. Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia. Although there is monthly fluctuation of the white blood cell count, specifically the CD4 and CD8 counts, there was no cumulative decline in the patient described in this case report. Depriving patients of this agent, in order to treat with immunotherapy, is controversial. Despite conventional dogma, we demonstrated that chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery.

 

Key Words: active immunotherapy • antibody • antigen • CNS neoplasms • cytotoxic T lymphocyte • epidermal growth factor receptor • glioma

For full text: http://neuro-oncology.dukejournals.org/cgi/content/abstract/10/1/98?etoc


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740